Banner for leaf pages 2

Aripiprazole (Abilify)

Also known as Abilify

Aripiprazole is a partial dopamine agonist of the second generation class of atypical antipsychotics with additional antidepressant properties that is primarily used in the treatment of schizophrenia, bipolar disorder, and major depressive disorder. It was approved by the U.S. Food and Drug Administration (FDA) for schizophrenia on November 15, 2002 and the European Medicines Agency on 4 June 2004; for acute manic and mixed episodes associated with bipolar disorder on October 1, 2004; as an adjunct for major depressive disorder on November 20, 2007; and to treat irritability in children with autism on 20 November 2009. Aripiprazole was developed by Otsuka in Japan, and in the United States, Otsuka America markets it jointly with Bristol-Myers Squibb.

Source: Wikipedia

Estimated Total Cost: $496.92 for an average of 28 days supply

What is it prescribed for?

Patients are most commonly prescribed aripiprazole to treat bipolar disorder, schizophrenia, depressive or psychotic symptoms, and psychotic disorder.

What drug interactions are known?

Do not take aripiprazole if you are taking any of the following:

Critical Interactions

Significant Interactions

Ajax-loader Loading...